7,556 Shares in Metsera Inc. $MTSR Bought by Corebridge Financial Inc.

Key Points

• Corebridge Financial Inc. acquired 7,556 shares of Metsera Inc. valued at approximately $206,000 in Q1, marking a significant investment in the company.
• Analysts have mixed opinions on Metsera's stock, with Wells Fargo setting an "overweight" rating and a $65 target price, while Wall Street Zen downgraded it to a "sell" rating.
• Metsera's stock is currently trading at $35.10, showing a decline of 2.1%, with an average target price among analysts set at $59.00.

Corebridge Financial Inc. bought a new position in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 7,556 shares of the company's stock, valued at approximately $206,000.

Several other hedge funds have also recently bought and sold shares of MTSR. New York State Common Retirement Fund acquired a new position in Metsera during the first quarter worth $131,000. MetLife Investment Management LLC acquired a new position in Metsera during the first quarter worth $254,000. Invesco Ltd. acquired a new position in Metsera during the first quarter worth $271,000. Deutsche Bank AG acquired a new position in Metsera during the first quarter worth $374,000. Finally, Nuveen LLC acquired a new position in Metsera during the first quarter worth $553,000.

Wall Street Analysts Forecast Growth

Several research firms have commented on MTSR. Wells Fargo & Company began coverage on shares of Metsera in a research report on Friday, June 20th. They set an "overweight" rating and a $65.00 target price on the stock. Wall Street Zen downgraded shares of Metsera from a "hold" rating to a "sell" rating in a research report on Sunday. Cantor Fitzgerald reissued an "overweight" rating on shares of Metsera in a research report on Wednesday, September 3rd. Bank of America raised their price target on Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. Finally, Guggenheim raised their price target on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday, June 10th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $59.00.

Metsera Stock Down 2.1%

Shares of NASDAQ:MTSR opened at $35.10 on Tuesday. The stock's 50-day moving average is $34.86 and its 200-day moving average is $28.65. Metsera Inc. has a 52-week low of $12.30 and a 52-week high of $47.40.

Metsera (NASDAQ:MTSR - Get Free Report) last issued its quarterly earnings results on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.